184 related articles for article (PubMed ID: 793705)
21. [Treatment with antilymphocyte globulin (ALG) and evolution of renal transplant: observations of 42 cases].
Civati G; Grillo C; Di Belgioioso GB; Rovati C; Surian M; Busnach G; Broggi L; Ferrari L
Boll Ist Sieroter Milan; 1978 May; 57(2):165-72. PubMed ID: 365193
[TBL] [Abstract][Full Text] [Related]
22. Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring.
Cosimi AB; Wortis HH; Delmonico FL; Russell PS
Surgery; 1976 Aug; 80(2):155-63. PubMed ID: 781887
[TBL] [Abstract][Full Text] [Related]
23. Clinical use of rabbit antihuman lymphocyte globulin in cadaver-kidney transplantation.
Mannick JA; Davis RC; Cooperband SR; Glasgow AH; Williams LF; Harrington JT; Cavallo T; Schmitt GW; Idelson BA; Olsson CA; Nabseth DC
N Engl J Med; 1971 May; 284(20):1109-15. PubMed ID: 4928659
[No Abstract] [Full Text] [Related]
24. Is sequential low-dose immunotherapy the preferred treatment in cadaveric renal transplantation?
Posner MP; Mendez-Picon G; King A; Nelson KP; Spicer HG; Lee HM
Transplant Proc; 1989 Feb; 21(1 Pt 2):1594-7. PubMed ID: 2652519
[No Abstract] [Full Text] [Related]
25. The adjunctive value of equine antithymocyte membrane globulin in a randomized study of patients undergoing cadaveric renal transplantation.
Diethelm AG; Blackstone E; Whelchel JD; Pass RF; Chambers L; Phillips SJ; Thiry C
Transplant Proc; 1979 Mar; 11(1):27-30. PubMed ID: 377644
[No Abstract] [Full Text] [Related]
26. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
Grimbert P; Baron C; Fruchaud G; Hemery F; Desvaux D; Buisson C; Chopin D; Dahmane D; Remy P; Pastural M; Abbou C; Weil B; Lang P
Transpl Int; 2002 Nov; 15(11):550-5. PubMed ID: 12461659
[TBL] [Abstract][Full Text] [Related]
27. One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.
Colak T; Sevmiş S; Karakayali H; Moray G; Haberal M
Transplant Proc; 2008; 40(1):123-5. PubMed ID: 18261564
[TBL] [Abstract][Full Text] [Related]
28. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
Guttmann RD; Flemming C
Clin Transplant; 1997 Jun; 11(3):185-92. PubMed ID: 9193840
[TBL] [Abstract][Full Text] [Related]
29. A controlled trial of antihuman lymphocyte globulin (Behring) in cadaveric renal transplantation: improvement in graft and patient survival at one year using a high-dose regimen.
Groth CG; Berg B; Collste H; Lundgren G; Magnusson G; Ringdén O; Pieper R
Scand J Urol Nephrol Suppl; 1977; (42):83-5. PubMed ID: 356230
[TBL] [Abstract][Full Text] [Related]
30. Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt.
Monaco AP; Clark AW; Wood ML; Sahyoun AI; Codish SD; Brown RW
Surgery; 1976 Apr; 79(4):384-92. PubMed ID: 769219
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
[No Abstract] [Full Text] [Related]
32. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
[TBL] [Abstract][Full Text] [Related]
33. Treatment of multiple rejection episodes with ALG or ATGAM after cadaveric renal transplantation.
Toledo-Pereya LH; Whitten J; Baskin S; McNichol L; Thavarajah K; Lin W
Bol Asoc Med P R; 1984 Jul; 76(7):293-6. PubMed ID: 6383417
[No Abstract] [Full Text] [Related]
34. [Clinical significance of immunological findings for the survival time of kidney transplants with antilymphocyte globulin therapy].
Bullinger W; Hammer C; Land W; Welter H
Chir Forum Exp Klin Forsch; 1979; ():319-24. PubMed ID: 378592
[TBL] [Abstract][Full Text] [Related]
35. An evaluation of early cyclosporine versus ALG therapy for primary cadaver renal allografts with immediate function.
Adams MB; Johnson CP; Roza AM
Transplant Proc; 1989 Feb; 21(1 Pt 2):1606-8. PubMed ID: 2652523
[No Abstract] [Full Text] [Related]
36. Cyclosporine-steroids versus conventional therapy in cadaver kidney transplantation: analysis of a randomized trial at two years.
Gianello P; Squifflet JP; Pirson Y; Stoffel M; Dereme T; Alexandre GP
Transplant Proc; 1987 Feb; 19(1 Pt 3):1867-72. PubMed ID: 3547891
[No Abstract] [Full Text] [Related]
37. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection.
Khosroshahi HT; Tubbs RS; Shoja MM; Ghafari A; Noshad H; Ardalan MR
Transplant Proc; 2008; 40(1):137-9. PubMed ID: 18261569
[TBL] [Abstract][Full Text] [Related]
38. Antilymphocyte globulin for the treatment of steroid non-responsive acute renal allograft rejection.
Griffin PJ; Williams GT; Salaman JR
Clin Nephrol; 1984 Feb; 21(2):115-7. PubMed ID: 6373078
[TBL] [Abstract][Full Text] [Related]
39. A controlled randomized double-blind study of antilymphoblast globulin in cadaver renal transplantation.
Novick AC; Braun WE; Steinmuller D; Buszta C; Greenstreet R; Kiser W
Transplantation; 1983 Feb; 35(2):175-9. PubMed ID: 6338636
[TBL] [Abstract][Full Text] [Related]
40. The role of antilymphocyte globulin in cadaver renal transplantation.
Novick AC
Transplant Proc; 1986 Jun; 18(3 Suppl 2):22-7. PubMed ID: 3521000
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
